Expansions, New Leadership, Annual Award Winners, FDA Approvals, and Abstracts Presentations - Analyst Notes on AbbVie, Amgen, Regeneron Pharmaceuticals Inc, Valeant Pharmaceuticals and Lilly

NEW YORK, June 12, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding AbbVie Inc. (NYSE: ABBV), Amgen, Inc. (NASDAQ: AMGN), Regeneron (NASDAQ: REGN), Valeant Pharmaceuticals Intl Inc (NYSE: VRX) and Eli Lilly and Co (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3638-100free.

--
AbbVie Inc. Analyst Notes
On June 3, 2014, AbbVie Inc (AbbVie) reported that its Chairman and CEO, Richard A. Gonzales, along with other senior leaders of the Company, officially inaugurated its newly expanded facility in Sligo, Ireland. AbbVie reported that the new site is a strategic asset for the Company because of its involvement in the commercialization and manufacturing of AbbVie pipeline products in liver disease, oncology, and women's health. This expansion also provides increased the manufacturing capacity to deliver on AbbVie's existing portfolio of medicines and to support potential new therapies within AbbVie's pipeline. "This investment represents our ongoing commitment to Sligo and Ireland as an important part of AbbVie's biopharmaceutical manufacturing strategy," said Azita Saleki-Gerhardt, Ph.D., Senior Vice President, Operations, AbbVie. The full analyst notes on AbbVie are available to download free of charge at:

http://www.analystsreview.com/Jun-12-2014/ABBV/report.pdf

--
Amgen, Inc. Analyst Notes
On June 9, 2014, Amgen, Inc. (Amgen) announced that David W. Meline has been appointed as Executive Vice President and CFO, effective July 21, 2014. According to the Company, Mr. Meline in his new role will succeed Michael A. Kelly, who served as acting CFO of Amgen since January 2014 and will be responsible for Amgen's finance and investor relations operations. Mr. Meline most recently served as 3M Company's Senior Vice President and CFO, handling all financial activities for 3M across 70 countries of operation. "David's leadership talent and broad international experience will be invaluable to Amgen as we execute our strategy for long term growth and bring our pipeline of medicines toward commercialization in a number of new markets. I am delighted to welcome him to the team." said Chairman and CEO of Amgen, Robert A. Bradway. The full analyst notes on Amgen are available to download free of charge at:

http://www.analystsreview.com/Jun-12-2014/AMGN/report.pdf

--
Regeneron Analyst Notes
On June 2, 2014, Regeneron Pharmaceuticals Inc (Regeneron) announced the winners of the 2014 Regeneron Prize for Creative Innovation award that acknowledges, rewards, and fosters talented early-career biomedical scientists. Regeneron reported that in 2014, the 10 awardees and two institutions received $160,000 in prize money of which, two winners will each receive a $50,000 cash prize. Additionally, two graduate student researchers will receive Honorable Mentions and a cash prize of $10,000 each. Six additional finalists will receive $5,000 each. George Yancopoulos, M.D., Ph.D., Founding Scientist, President, Regeneron Laboratories, and Chief Scientific Officer said, "The Regeneron Prize for Creative Innovation identifies and recognizes young scientists who show great promise to become the next generation of leading innovators in our industry." The full analyst notes on Regeneron Pharmaceuticals Inc are available to download free of charge at:

http://www.analystsreview.com/Jun-12-2014/REGN/report.pdf

--
Valeant Pharmaceuticals Intl Inc Analyst Notes
On June 9, 2014, Valeant Pharmaceuticals North America LLC, a wholly owned subsidiary of Valeant Pharmaceuticals Intl Inc (Valeant Pharmaceuticals) announced that the U.S. Food and Drug Administration (FDA) has approved the new Drug Application (NDA) for Jubila® (eficonazole 10% topical solution), the first topical triazole antifungal agent approved for the treatment of onychomycosis of the toenails. J. Michael Pearson, Chairman and CEO, Valeant Pharmaceuticals said, "We are working quickly to get this important product launched in the U.S. and Canada in the Q3 2014. We anticipate favorable managed care coverage in the U.S., similar to other branded antifungal agents, with peak sales of $300-$800 million in the U.S. alone and we are also working with other regulatory agencies around the world on further approvals." The full analyst notes on Valeant Pharmaceuticals are available to download free of charge at:

http://www.analystsreview.com/Jun-12-2014/VRX/report.pdf

--
Eli Lilly and Co Analyst Notes
On June 9, 2014, Eli Lilly and Co (Lilly) announced that it will present 76 abstracts at the 74th American Diabetes Association Scientific Sessions® from June 13, 2014 to June 17, 2014, in San Francisco. According to the Company, of the 76 abstracts, 43 will be presented as part of the Boehringer Ingelheim-Lilly Diabetes Alliance. Gwen Krivi, Ph.D., Vice President, Diabetes Product Development of Lilly said, "These Scientific Sessions provide an important opportunity for both Lilly and our Alliance to share new data from our broad diabetes portfolio, including data on investigational treatments from our pipeline. Lilly's commitment to serving the diverse needs of people with diabetes will be on full display next week in San Francisco." The full analyst notes on Lilly are available to download free of charge at:

http://www.analystsreview.com/Jun-12-2014/LLY/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com .

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com .

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review